Condition: Non Small Cell Lung Cancer · Sponsor: Fudan University
This study is a single arm study to access the anti-tumor efficacy and safety of sunvozertinib in untreated advanced NSCLC patients with EGFR uncommon mutations.
This description comes directly from the study's public registry record.
Jialei Wang · 18017312369 · wangjialei@shca.org.cn
Always discuss trial participation with your own doctor first.
| Fudan university shanghai cancer center | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07117890